Analyst Research Report Snapshot

Title:

ACTELION - THE DEVIL'S IN THE DATA

Price:

$10.00

Provider:

Edison Investment Research

Date:

19 Feb 2010

Pages:

2

Type:

AcrobatPDF

Companies referenced:

ATLN.VX

Available for Immediate Download
Summary:

At first glance, Actelion’s development pipeline is impressive, with five Phase III programmes supplementing the solid performance of its three marketed products. However, significant uncertainty remains ahead of potentially transformative, albeit risky, clinical catalysts: BUILD-3 results for Tracleer in idiopathic pulmonary fibrosis in Q1, followed by CONSCIOUS-2 clazosentan data in aneurysmal subarachnoid haemorrhage in H2.

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.